Cargando…

Role of Nuclear Claudin-4 in Renal Cell Carcinoma

Claudin-4 (CLDN4) is a tight junction protein to maintain the cancer microenvironment. We recently reported the role of the CLDN4 not forming tight junction in the induction of epithelial-mesenchymal transition (EMT). Herein, we investigated the role of CLDN4 in renal cell carcinoma (RCC), focusing...

Descripción completa

Detalles Bibliográficos
Autores principales: Owari, Takuya, Sasaki, Takamitsu, Fujii, Kiyomu, Fujiwara-Tani, Rina, Kishi, Shingo, Mori, Shiori, Mori, Takuya, Goto, Kei, Kawahara, Isao, Nakai, Yasushi, Miyake, Makito, Luo, Yi, Tanaka, Nobumichi, Kondoh, Masuo, Fujimoto, Kiyohide, Kuniyasu, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664319/
https://www.ncbi.nlm.nih.gov/pubmed/33172177
http://dx.doi.org/10.3390/ijms21218340
_version_ 1783609819849031680
author Owari, Takuya
Sasaki, Takamitsu
Fujii, Kiyomu
Fujiwara-Tani, Rina
Kishi, Shingo
Mori, Shiori
Mori, Takuya
Goto, Kei
Kawahara, Isao
Nakai, Yasushi
Miyake, Makito
Luo, Yi
Tanaka, Nobumichi
Kondoh, Masuo
Fujimoto, Kiyohide
Kuniyasu, Hiroki
author_facet Owari, Takuya
Sasaki, Takamitsu
Fujii, Kiyomu
Fujiwara-Tani, Rina
Kishi, Shingo
Mori, Shiori
Mori, Takuya
Goto, Kei
Kawahara, Isao
Nakai, Yasushi
Miyake, Makito
Luo, Yi
Tanaka, Nobumichi
Kondoh, Masuo
Fujimoto, Kiyohide
Kuniyasu, Hiroki
author_sort Owari, Takuya
collection PubMed
description Claudin-4 (CLDN4) is a tight junction protein to maintain the cancer microenvironment. We recently reported the role of the CLDN4 not forming tight junction in the induction of epithelial-mesenchymal transition (EMT). Herein, we investigated the role of CLDN4 in renal cell carcinoma (RCC), focusing on CLDN4. CLDN4 expression in 202 RCCs was examined by immunostaining. CLDN4 phosphorylation and subcellular localization were examined using high metastatic human RCC SN12L1 and low metastatic SN12C cell lines. In 202 RCC cases, the CLDN4 expression decreased in the cell membrane and had no correlation with clinicopathological factors. However, CLDN4 was localized in the nucleus in 5 cases (2%), all of which were pT3. Contrastingly, only 6 of 198 nuclear CLDN4-negative cases were pT3. CLDN4 was found in the nuclear fraction of a highly metastatic human RCC cell line, SN12L1, but not in the low metastatic SN12C cells. In SN12L1 cells, phosphorylation of tyrosine and serine residues was observed in cytoplasmic CLDN4, but not in membranous CLDN4. In contrast, phosphorylation of serine residues was observed in nuclear CLDN4. In SN12L1 cells, CLDN4 tyrosine phosphorylation by EphA2/Ephrin A1 resulted in the release of CLDN4 from tight junction and cytoplasmic translocation. Furthermore, protein kinase C (PKC)-ε phosphorylated the CLDN4 serine residue, resulting in nuclear import. Contrarily, in SN12C cells that showed decreased expression of EphA2/Ephrin A1 and PKCε, the activation of EphA2/EphrinA1 and PKCε induced cytoplasmic and nuclear translocation of CLDN4, respectively. Furthermore, the nuclear translocation of CLDN4 promoted the nuclear translocation of Yes-associated protein (YAP) bound to CLDN4, which induced the EMT phenotype. These findings suggest that the release of CLDN4 by impaired tight junction might be a mechanism underlying the malignant properties of RCC. These findings suggest that the release of CLDN4 by impaired tight junction might be one of the mechanisms of malignant properties of RCC.
format Online
Article
Text
id pubmed-7664319
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76643192020-11-14 Role of Nuclear Claudin-4 in Renal Cell Carcinoma Owari, Takuya Sasaki, Takamitsu Fujii, Kiyomu Fujiwara-Tani, Rina Kishi, Shingo Mori, Shiori Mori, Takuya Goto, Kei Kawahara, Isao Nakai, Yasushi Miyake, Makito Luo, Yi Tanaka, Nobumichi Kondoh, Masuo Fujimoto, Kiyohide Kuniyasu, Hiroki Int J Mol Sci Article Claudin-4 (CLDN4) is a tight junction protein to maintain the cancer microenvironment. We recently reported the role of the CLDN4 not forming tight junction in the induction of epithelial-mesenchymal transition (EMT). Herein, we investigated the role of CLDN4 in renal cell carcinoma (RCC), focusing on CLDN4. CLDN4 expression in 202 RCCs was examined by immunostaining. CLDN4 phosphorylation and subcellular localization were examined using high metastatic human RCC SN12L1 and low metastatic SN12C cell lines. In 202 RCC cases, the CLDN4 expression decreased in the cell membrane and had no correlation with clinicopathological factors. However, CLDN4 was localized in the nucleus in 5 cases (2%), all of which were pT3. Contrastingly, only 6 of 198 nuclear CLDN4-negative cases were pT3. CLDN4 was found in the nuclear fraction of a highly metastatic human RCC cell line, SN12L1, but not in the low metastatic SN12C cells. In SN12L1 cells, phosphorylation of tyrosine and serine residues was observed in cytoplasmic CLDN4, but not in membranous CLDN4. In contrast, phosphorylation of serine residues was observed in nuclear CLDN4. In SN12L1 cells, CLDN4 tyrosine phosphorylation by EphA2/Ephrin A1 resulted in the release of CLDN4 from tight junction and cytoplasmic translocation. Furthermore, protein kinase C (PKC)-ε phosphorylated the CLDN4 serine residue, resulting in nuclear import. Contrarily, in SN12C cells that showed decreased expression of EphA2/Ephrin A1 and PKCε, the activation of EphA2/EphrinA1 and PKCε induced cytoplasmic and nuclear translocation of CLDN4, respectively. Furthermore, the nuclear translocation of CLDN4 promoted the nuclear translocation of Yes-associated protein (YAP) bound to CLDN4, which induced the EMT phenotype. These findings suggest that the release of CLDN4 by impaired tight junction might be a mechanism underlying the malignant properties of RCC. These findings suggest that the release of CLDN4 by impaired tight junction might be one of the mechanisms of malignant properties of RCC. MDPI 2020-11-06 /pmc/articles/PMC7664319/ /pubmed/33172177 http://dx.doi.org/10.3390/ijms21218340 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Owari, Takuya
Sasaki, Takamitsu
Fujii, Kiyomu
Fujiwara-Tani, Rina
Kishi, Shingo
Mori, Shiori
Mori, Takuya
Goto, Kei
Kawahara, Isao
Nakai, Yasushi
Miyake, Makito
Luo, Yi
Tanaka, Nobumichi
Kondoh, Masuo
Fujimoto, Kiyohide
Kuniyasu, Hiroki
Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title_full Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title_fullStr Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title_full_unstemmed Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title_short Role of Nuclear Claudin-4 in Renal Cell Carcinoma
title_sort role of nuclear claudin-4 in renal cell carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664319/
https://www.ncbi.nlm.nih.gov/pubmed/33172177
http://dx.doi.org/10.3390/ijms21218340
work_keys_str_mv AT owaritakuya roleofnuclearclaudin4inrenalcellcarcinoma
AT sasakitakamitsu roleofnuclearclaudin4inrenalcellcarcinoma
AT fujiikiyomu roleofnuclearclaudin4inrenalcellcarcinoma
AT fujiwaratanirina roleofnuclearclaudin4inrenalcellcarcinoma
AT kishishingo roleofnuclearclaudin4inrenalcellcarcinoma
AT morishiori roleofnuclearclaudin4inrenalcellcarcinoma
AT moritakuya roleofnuclearclaudin4inrenalcellcarcinoma
AT gotokei roleofnuclearclaudin4inrenalcellcarcinoma
AT kawaharaisao roleofnuclearclaudin4inrenalcellcarcinoma
AT nakaiyasushi roleofnuclearclaudin4inrenalcellcarcinoma
AT miyakemakito roleofnuclearclaudin4inrenalcellcarcinoma
AT luoyi roleofnuclearclaudin4inrenalcellcarcinoma
AT tanakanobumichi roleofnuclearclaudin4inrenalcellcarcinoma
AT kondohmasuo roleofnuclearclaudin4inrenalcellcarcinoma
AT fujimotokiyohide roleofnuclearclaudin4inrenalcellcarcinoma
AT kuniyasuhiroki roleofnuclearclaudin4inrenalcellcarcinoma